About J.B. Chemicals & Pharmaceuticals Limited

J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) is a public limited company incorporated in India and listed on both BSE Limited (BSE) and the National Stock Exchange of India Limited (NSE). Established 49 years ago, JB Pharma has built a strong legacy in the pharmaceutical industry through the manufacture and marketing of pharmaceutical formulations, herbal products, active pharmaceutical ingredients (APIs), and product development services.

The Company’s diverse product portfolio includes tablets, capsules, herbal syrups, lozenges, and injectables, catering to therapeutic areas such as Cough & Cold (Respiratory), Dermatology, Gastroenterology, Cardiology, and Radiology. JB Pharma is among the few Indian pharmaceutical companies to implement OROS (osmotic-controlled release oral drug delivery system) technology and is a global leader in lozenge manufacturing, ranking among the top five producers of medicated and herbal lozenges worldwide.

JB Pharma serves both domestic and international markets, exporting to over 40 regulated and semi-regulated countries through direct operations and distributors. Generics are exported to the USA, UK, South Africa, Australia, and Canada, while branded generics are supplied to Africa, South-East Asia, the Gulf, the Middle East, Central, and South America. The Company’s USA generics business follows an asset-light distributor model, with over 17 ANDAs approved in that market.

The Company operates eight state-of-the-art multi-dosage formulation plants with key global regulatory approvals and employs a workforce of more than 5,000, including a 2,800+ strong India field force. JB Pharma has four international subsidiaries supporting its global presence.

Key milestones include ranking among the top 10 companies in cardiology (with three brands in the top 25 of the therapy) and having six iconic brands among the top 300 pharmaceutical brands in India (IQVIA MAT March 2025). Within India, 75% of domestic business is derived from pillar brands in fast-growing segments such as probiotics, hypertension, heart failure, lipid management, ophthalmology, and paediatrics. The Company also identifies Russia and South Africa as “home markets” alongside India for its branded generics portfolio.

J.B. Chemicals & Pharmaceuticals Limited Key Business Segments

By Business Unit (FY 2024–25):

• Domestic Formulations – 58% of revenues 
• CDMO (Contract Development and Manufacturing, including lozenges) – 11% of total revenues 

By Geography (FY 2024–25):

• Exports – 38% of total turnover 
• Domestic – 62% (balance) 

J.B. Chemicals & Pharmaceuticals Limited Key Management

• Nikhil Chopra – Chief Executive Officer & Whole-Time Director 
• Narayan Saraf – Chief Financial Officer 
• Sandeep Phadnis – Company Secretary 
• Kunal Khanna – President – Operations 
• Dilip Singh Rathore – President – Sales & Marketing 
• Pradeep Kumar Singh – President – Global Business 
• Dr. Sujay Rajhans – President – R&D 
• Parmeshwar Bang – Executive Vice President – Operations 

Latest Updates on J.B. Chemicals & Pharmaceuticals Limited

• Strategic transaction: Torrent Pharmaceuticals Limited entered into definitive agreements to acquire a controlling stake in JB Pharma from KKR at an equity valuation of Rs 25,689 crore. Phase 1 includes the acquisition of 46.39% equity via a Share Purchase Agreement worth Rs 11,917 crore (Rs 1,600 per share), to be followed by a full merger subject to statutory and regulatory approvals. 
• Portfolio expansion: The Company entered into a perpetual trademark licence agreement with Novartis Innovative Therapies AG (Switzerland) for an ophthalmology portfolio, alongside a three-year promotion and distribution agreement with Novartis Healthcare Private Limited effective December 2023. The portfolio comprises 10 brands, including Simbrinza, Travatan, Azopt, and Pataday, five of which hold leadership positions in their molecule categories. 
• Ophthalmology momentum: The newly acquired ophthalmology franchise achieved double-digit growth in its first year under JB Pharma’s management. 
• International focus shift: In South Africa, the Company strategically reduced low-margin tender exposure to focus on the private market, maintaining profitability despite temporary moderation in segment growth. 
• CDMO pipeline: The CDMO division secured global projects scheduled for commercialisation within 12–18 months, reinforcing JB Pharma’s leadership in lozenges and its R&D-driven product development capabilities. 

Market standing: JB Pharma rose to rank #22 in the Indian Pharmaceutical Market (IQVIA MAT March 2025), backed by strong performance in chronic therapies and six brands among the top 300 in India.